UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in GLUE — Monte Rosa Therapeutics, Inc.

CIK 861177 NEW YORK, NY

Back to GLUE Full portfolio

Position in GLUE

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$1,583,913

+$1,266,774 QoQ

Shares Held

65,451

+239.5% QoQ

Ownership

0.077%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#85

of 193 holders

Holding Since

Jun 2024

7 quarters on record

Voting authority Sole 38% Shared 0% None 62%

Common Shares in GLUE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,385,897,555 across 206 Biotechnology names. GLUE ranks #107 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,086,683	$1,533,248,041
2	REGN	Regeneron Pharmaceuticals, Inc.	716,560	$446,803,817
3	ALNY	Alnylam Pharmaceuticals, Inc.	727,848	$219,104,078
4	INCY	Incyte Corp	1,508,720	$171,028,494
5	RVMD	Revolution Medicines, Inc.	912,335	$170,862,094
6	INSM	INSMED Inc	1,335,071	$142,345,265
7	IONS	Ionis Pharmaceuticals Inc	1,454,672	$115,340,938
8	MRNA	Moderna, Inc.	1,521,849	$106,575,080

All Filings in GLUE

Export CSV

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,583,913	65,451	+239.5%	Shares	Defined	2026-08-13
2026-03-31	$317,139	19,279	+3282.3%	Shares	Defined	2026-05-13
2025-12-31	$8,937	570	-97.6%	Shares	Defined	2026-02-13
2025-06-30	$108,691	24,100	0.0%	Shares	Defined	2025-08-14
2025-03-31	$111,824	24,100	0.0%	Shares	Defined	2025-05-19
2024-09-30	$127,730	24,100	+54.5%	Shares	Defined	2024-11-14
2024-06-30	$58,344	15,600	—	Shares	Defined	2024-08-14
No filing history on record for this holder in this stock.